OPTIMIZING STATIN THERAPY IN THE MANAGEMENT OF ISCHEMIC HEART DISEASE: A CLINICAL ASSESSMENT OF HIGH-INTENSITY REGIMENS AND ADHERENCE FACTORS

Abstract

Ischemic heart disease (IHD) remains the leading cause of mortality in Uzbekistan, necessitating aggressive lipid-lowering strategies. Despite clear international guidelines, the utilization of high-intensity statin therapy remains suboptimal due to concerns regarding side effects and poor patient adherence. This article presents a prospective clinical study conducted at the Department of Cardiology of Andijan State Medical Institute. Using the IMRAD framework, the research evaluates the efficacy and safety of high-intensity Rosuvastatin therapy in patients with stable angina and post-myocardial infarction status. The study involved 200 patients randomized into a standard care group and an intensified education-monitoring group. The results demonstrate that patients receiving intensified support achieved guideline-directed LDL-cholesterol targets significantly more often (65 percent vs 30 percent) without a significant increase in hepatic or muscular adverse events. The study concludes that the primary barrier to effective statin therapy is not biological intolerance but rather psychosocial resistance, which can be overcome through targeted education and monitoring.